Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

University of Guelph

$17,500.00

Efficacy of Combination Therapy of 3TSR Fusion Proteins and Chemotherapeutics on Ovarian Cancer

EF 2013-14

Résumé
According to the Canadian Cancer Society, over 2,600 Canadian women will be diagnosed with ovarian cancer in 2013 and approximately 1750 women will succumb to this deadly disease. As the fifth leading cause of death among women, ovarian cancer, and in particular epithelial ovarian cancer (EOC), is both the most common and the most deadly of all the gynecological disorders. Late stage detection and inadequate treatment options contribute to this high mortality rate. Blood vessel growth and development are key mediators of tumour development, providing the cancer cells with a steady supply of nutrients and oxygen. A key characteristic of tumour vessels is that they tend to be less mature and are dysfunctional when compared to healthy blood vessels. The work in Dr. Jim Petrik’s lab at the University of Guelph has focused on this blood vessel characteristic. Recently Dr. Petrik’s lab validated the efficacy of a protein known as 3TSR as a therapeutic agent for EOC treatment, particularly when used in combination with chemotherapy agents. Interestingly, 3TSR is able to rid tumours of their immature blood vessels and promote normalization of their existing blood vessels. In addition, 3TSR is able to promote death of the tumour cells. Combining the vascular effects of 3TSR with traditional chemotherapy agents has shown particular effectiveness in promoting tumour regression and inducing regression of advanced stage disease. Results to date show that normalizing blood vessels through the actions of 3TSR can promote better uptake of the chemotherapy drugs by the tumour and thus maximize their anti-cancer effects. While 3TSR has shown promising results thus far, its small molecular size results in rapid degradation and is a biological limitation. In order to maximize the efficacy of 3TSR, a fusion protein has been developed which combines 2 functional molecules of 3TSR, resulting in a larger structure, with increased biological activity and prolonged activity. I believe this larger, newly developed protein known as Fc-3TSR may hold significant promise as an anti-cancer agent, particularly in combination with a traditional chemotherapy regimen. I intend to begin my research into the study of Fc-3TSR as a therapeutic agent at the cellular level; preliminary work with in vitro trials will demonstrate the effect of this agent on cultured ovarian cancer cells. Following this preliminary work I propose to study the potential of Fc-3TSR to inhibit tumour growth and promote regression of ovarian cancer in a mouse model of EOC, both as the primary therapeutic intervention and in combination with chemotherapy drugs. My hope is that the results of this research will further our understanding of effective ovarian cancer treatment strategies and may represent a new therapeutic option for the treatment of EOC.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
311914
Name
ten Kortenaar Simone R
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Efficacy of Combination Therapy of 3TSR Fusion Proteins and Chemotherapeutics on Ovarian Cancer
Programtype2
Studentship Programs
Orgnameinp2
University of Guelph
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Angiogenesis; Apoptosis; Chemotherapy; Combinational Therapy; Oncology; Ovarian Cancer
Abstract
According to the Canadian Cancer Society, over 2,600 Canadian women will be diagnosed with ovarian cancer in 2013 and approximately 1750 women will succumb to this deadly disease. As the fifth leading cause of death among women, ovarian cancer, and in particular epithelial ovarian cancer (EOC), is both the most common and the most deadly of all the gynecological disorders. Late stage detection and inadequate treatment options contribute to this high mortality rate. Blood vessel growth and development are key mediators of tumour development, providing the cancer cells with a steady supply of nutrients and oxygen. A key characteristic of tumour vessels is that they tend to be less mature and are dysfunctional when compared to healthy blood vessels. The work in Dr. Jim Petrik’s lab at the University of Guelph has focused on this blood vessel characteristic. Recently Dr. Petrik’s lab validated the efficacy of a protein known as 3TSR as a therapeutic agent for EOC treatment, particularly when used in combination with chemotherapy agents. Interestingly, 3TSR is able to rid tumours of their immature blood vessels and promote normalization of their existing blood vessels. In addition, 3TSR is able to promote death of the tumour cells. Combining the vascular effects of 3TSR with traditional chemotherapy agents has shown particular effectiveness in promoting tumour regression and inducing regression of advanced stage disease. Results to date show that normalizing blood vessels through the actions of 3TSR can promote better uptake of the chemotherapy drugs by the tumour and thus maximize their anti-cancer effects. While 3TSR has shown promising results thus far, its small molecular size results in rapid degradation and is a biological limitation. In order to maximize the efficacy of 3TSR, a fusion protein has been developed which combines 2 functional molecules of 3TSR, resulting in a larger structure, with increased biological activity and prolonged activity. I believe this larger, newly developed protein known as Fc-3TSR may hold significant promise as an anti-cancer agent, particularly in combination with a traditional chemotherapy regimen. I intend to begin my research into the study of Fc-3TSR as a therapeutic agent at the cellular level; preliminary work with in vitro trials will demonstrate the effect of this agent on cultured ovarian cancer cells. Following this preliminary work I propose to study the potential of Fc-3TSR to inhibit tumour growth and promote regression of ovarian cancer in a mouse model of EOC, both as the primary therapeutic intervention and in combination with chemotherapy drugs. My hope is that the results of this research will further our understanding of effective ovarian cancer treatment strategies and may represent a new therapeutic option for the treatment of EOC.
Competitiondate
201312
Approvedterm2
1 yr 0 mth
Pinamesdelim
ten Kortenaar, Simone R
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~